Supriya Lifescience Limited (NSE: SUPRIYA, BSE: 543434) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,134 Cr, it ranks #827 by market cap among the 6,197 Indian listed companies on FinBizNet, and #25 of 86 in Medicinal Chemicals and Botanical Products. At ₹632.30 (as of 16 Nov 2026), the share price is 41.7% below its 52-week high of ₹1,085.00 and 15.9% above its 52-week low of ₹545.50. The share price is down 18.9% over one year and down 22.3% over three months.
| Current Price | ₹632.30 |
|---|---|
| Market Cap | ₹5,134 Cr |
| NSE Symbol | SUPRIYA |
| BSE Code | 543434 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 24.7 |
| Return on Equity | 19.06% |
| Return on Assets | 13.46% |
| 52-Week Range | ₹545.50 – ₹1,085.00 |
| 1-Year Price Change | -18.9% |
| 3-Month Price Change | -22.3% |
| Beta (1Y) | 0.76 |
| Dividend Yield | 0.16% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.supriyalifescience.com |
| Revenue | ₹206 Cr |
|---|---|
| Net Profit | ₹29 Cr |
| Net Margin | 14.2% |
| EPS (Basic) | ₹3.63 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Supriya Lifescience Limited reported revenue of ₹206 Cr in Q2 FY27, up 3.2% from ₹200 Cr in Q2 FY26 and up 8.7% from ₹190 Cr in Q1 FY27. It posted a net profit of ₹29 Cr for the quarter, against a net profit of ₹50 Cr in Q2 FY26 (down 42.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹145 Cr (Q1 FY26) to ₹277 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹206 Cr | ₹29 Cr | 14.2% |
| Q1 FY27 | ₹190 Cr | ₹24 Cr | 12.7% |
| Q4 FY26 | ₹277 Cr | ₹74 Cr | 26.8% |
| Q3 FY26 | ₹206 Cr | ₹50 Cr | 24.1% |
| Q2 FY26 | ₹200 Cr | ₹50 Cr | 25.2% |
| Q1 FY26 | ₹145 Cr | ₹35 Cr | 24.0% |
| Q4 FY25 | ₹184 Cr | ₹50 Cr | 27.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 68.30% of Supriya Lifescience Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 41.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
1. Specialty Chemicals-This segment engages in the research and development, manufacture, and sale of active pharmaceutical ingredients.
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Supriya Lifescience Limited | ₹5,134 Cr | 24.7 | 19.06% | ₹206 Cr | -18.9% |
Listed by market capitalisation. Ratios are shown for context only.
Supriya Lifescience Limited is trading at ₹632.30, with a market capitalisation of ₹5,134 Cr.
Supriya Lifescience Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Supriya Lifescience Limited has a P/E of 24.7 and a return on equity of 19.06%.
Supriya Lifescience Limited is listed on the NSE under the symbol SUPRIYA and on the BSE under the scrip code 543434.
Supriya Lifescience Limited's share price is down 18.9% over one year and down 22.3% over three months. Its 52-week range is ₹545.50 to ₹1,085.00.
In Q2 FY27, Supriya Lifescience Limited reported revenue of ₹206 Cr and net profit of ₹29 Cr, with basic EPS of ₹3.63 (standalone, parsed from the company's exchange filing).
Supriya Lifescience Limited reported revenue of ₹206 Cr in Q2 FY27, up 3.2% from ₹200 Cr in Q2 FY26 and up 8.7% from ₹190 Cr in Q1 FY27.
Promoters held 68.30% of Supriya Lifescience Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.